Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

Francis J. Giles, Eric J. Feldman, Gail J. Roboz, Richard A. Larson, Steven W. Mamus, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Moshe Talpaz, Miloslav Beran, Maher Albitar, Susan M. O'Brien, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m2 per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.

Original languageEnglish (US)
Pages (from-to)1091-1096
Number of pages6
JournalLeukemia Research
Volume27
Issue number12
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nucleosides
Hand-Foot Syndrome
Stomatitis
Exanthema
Intravenous Infusions
Therapeutics
Imatinib Mesylate
formal glycol
troxacitabine

Keywords

  • Blast phase
  • Chronic myelogenous leukemia
  • Imatinib mesylate
  • Troxacitabine

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. / Giles, Francis J.; Feldman, Eric J.; Roboz, Gail J.; Larson, Richard A.; Mamus, Steven W.; Cortes, Jorge E.; Verstovsek, Srdan; Faderl, Stefan; Talpaz, Moshe; Beran, Miloslav; Albitar, Maher; O'Brien, Susan M.; Kantarjian, Hagop M.

In: Leukemia Research, Vol. 27, No. 12, 01.12.2003, p. 1091-1096.

Research output: Contribution to journalArticle

Giles, FJ, Feldman, EJ, Roboz, GJ, Larson, RA, Mamus, SW, Cortes, JE, Verstovsek, S, Faderl, S, Talpaz, M, Beran, M, Albitar, M, O'Brien, SM & Kantarjian, HM 2003, 'Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase', Leukemia Research, vol. 27, no. 12, pp. 1091-1096. https://doi.org/10.1016/S0145-2126(03)00094-8
Giles, Francis J. ; Feldman, Eric J. ; Roboz, Gail J. ; Larson, Richard A. ; Mamus, Steven W. ; Cortes, Jorge E. ; Verstovsek, Srdan ; Faderl, Stefan ; Talpaz, Moshe ; Beran, Miloslav ; Albitar, Maher ; O'Brien, Susan M. ; Kantarjian, Hagop M. / Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. In: Leukemia Research. 2003 ; Vol. 27, No. 12. pp. 1091-1096.
@article{f68551a70eea4366b5f7a49edd7f676e,
title = "Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase",
abstract = "A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m2 per day. Thirty-one patients, 29 (93{\%}) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4{\%}), hand-foot syndrome (18{\%}), and skin rash (12{\%}). Four patients (13{\%}) responded. Troxacitabine-based combinations merit study in IM-resistant CML.",
keywords = "Blast phase, Chronic myelogenous leukemia, Imatinib mesylate, Troxacitabine",
author = "Giles, {Francis J.} and Feldman, {Eric J.} and Roboz, {Gail J.} and Larson, {Richard A.} and Mamus, {Steven W.} and Cortes, {Jorge E.} and Srdan Verstovsek and Stefan Faderl and Moshe Talpaz and Miloslav Beran and Maher Albitar and O'Brien, {Susan M.} and Kantarjian, {Hagop M.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1016/S0145-2126(03)00094-8",
language = "English (US)",
volume = "27",
pages = "1091--1096",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

AU - Giles, Francis J.

AU - Feldman, Eric J.

AU - Roboz, Gail J.

AU - Larson, Richard A.

AU - Mamus, Steven W.

AU - Cortes, Jorge E.

AU - Verstovsek, Srdan

AU - Faderl, Stefan

AU - Talpaz, Moshe

AU - Beran, Miloslav

AU - Albitar, Maher

AU - O'Brien, Susan M.

AU - Kantarjian, Hagop M.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m2 per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.

AB - A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m2 per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.

KW - Blast phase

KW - Chronic myelogenous leukemia

KW - Imatinib mesylate

KW - Troxacitabine

UR - http://www.scopus.com/inward/record.url?scp=10744228148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228148&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(03)00094-8

DO - 10.1016/S0145-2126(03)00094-8

M3 - Article

C2 - 12921945

AN - SCOPUS:10744228148

VL - 27

SP - 1091

EP - 1096

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 12

ER -